Foundayo, an oral GLP-1 receptor agonist developed by Eli Lilly containing the active ingredient orforglipron, reduces the predicted ten-year risk of developing type 2 diabetes by up to 57 percent in adults with obesity or overweight over a 72-week treatment period, according to post-hoc analyses of the phase 3 ATTAIN-1 clinical trial published in Diabetes, Obesity and Metabolism.
In Plain English: The Clinical Takeaway
- What it is: Orforglipron is an oral GLP-1 receptor agonist that mimics the GLP-1 hormone, suppressing appetite, slowing stomach emptying, and improving blood sugar regulation.
- The core finding: Higher doses (up to 17.2 mg) lowered predicted type 2 diabetes risk by 57% and predicted cardiovascular risk by 18% compared to placebo.
- Practical difference: Unlike orales Semaglutid, orforglipron can be taken at any time of day, whereas orales Semaglutid must be taken on an empty stomach.
Dose-Dependent Risk Reduction and Trial Demographics
Led by Thomas Seck, the ATTAIN-1 trial evaluated varying dosages of orforglipron against a placebo group over 72 weeks. The analysis revealed a continuous, dose-dependent reduction in the predicted probability of developing type 2 diabetes. At a 5.5 mg daily dose, the calculated risk reduction stood at 45.0 percent. This figure increased to 50.0 percent at the 9 mg dose and reached 57.0 percent at the maximum dose of 17.2 mg. For cardiovascular risk, the highest dose of 17.2 mg yielded an estimated decrease of 18.0 percent compared to placebo, alongside measurable improvements in blood glucose, blood pressure, and cholesterol levels.
Additional evaluations from the ATTAIN-1 and ATTAIN-2 clinical programs focusing on participants aged 65 and older demonstrated a mean body weight reduction of up to 13 percent, contrasted with a 1.6 percent change in the placebo cohort. Among female participants, researchers documented a weight loss of up to 14 percent, translating to a 28-pound reduction from a 200-pound baseline weight. The underlying therapeutic mechanism relies on appetite suppression, slowed gastric emptying, and improved blood sugar regulation.
| Orforglipron Dose | Predicted Type 2 Diabetes Risk Reduction | Predicted Cardiovascular Risk Reduction |
|---|---|---|
| 5.5 mg | 45.0% | Not primary endpoint |
| 9.0 mg | 50.0% | Not primary endpoint |
| 17.2 mg | 57.0% | 18.0% |
Head-to-Head Efficacy Against Oral Semaglutid and Insulin Glargine
In a head-to-head study with 1,700 adults with uncontrolled type 2 diabetes, orforglipron was pitted against oral semaglutid. Orforglipron lowered the HbA1c-Wert by 2.2 points, whereas the comparator agent achieved a 1.4-point reduction. Nearly 70 percent of patients in the higher dose groups met their blood sugar target. Patients taking the maximum dose lost nearly 20 pounds, compared to an 11-pound reduction observed in the oral semaglutid group.
Further clinical data emerged from the ACHIEVE-4 trial, funded by Eli Lilly and encompassing 2,749 adults with type 2 diabetes and renal or cardiovascular conditions. Presented at the EASD congress and published in The Lancet, the study found that orforglipron achieved non-inferiority against insulin glargine after approximately two years of follow-up, registering a hazard ratio of 0.84 with 57 events under orforglipron versus 67 under glargine. At week 52, patients receiving orforglipron recorded a weight change of minus 8.8 percent, while the glargine group increased by 1.7 percent.
Contraindications & When to Consult a Doctor
The safety profile of Foundayo requires medical vigilance. Known risks include thyroid tumors including thyroid cancer, pancreatitis, dehydration, and gastrointestinal complaints such as nausea or stomach problems, which typically subside. Patients must monitor for warning signs such as neck swelling, hoarseness, or difficulty swallowing. Concurrent administration with other GLP-1 receptor agonists is excluded, and the medication is not recommended during pregnancy or lactation. Reduced calorie intake and increased exercise remain necessary.
Regulatory Milestones and Public Health Access
Regulatory validation advanced when the United Kingdom’s MHRA granted approval to orforglipron for weight management and type 2 diabetes on August 10, 2026, marking its first green light in Europe. Henry Gregg of the National Pharmacy Association highlighted counterfeiting risks associated with oral products and emphasized the necessity of uniform access across the public health system. In France, formal market authorization and reimbursement frameworks remain pending. While long-term real-world observational data continue to accumulate, ongoing clinical investigations are evaluating orforglipron for secondary indications including obstructive sleep apnea and stress urinary incontinence.
Worth a look
